Also categorized in BoardMoves:
Cloud Foundry Board Elects EMC CTO As Chair
x hide permanently

Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors


SAN DIEGO, July 17, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Dr. Shefali Agarwal has been appointed to the Company’s Board of Directors. Dr. Agarwal is currently the Chief Medical Officer of Epizyme, Inc...

Mentions: Nasdaq Epizyme Fate Therapeutics